Traws Pharma (TRAW) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Oct, 2026Executive summary
Special meeting scheduled for Dec. 3, 2026, at 9:00 a.m. ET; votes due by Dec. 2, 2026, at 11:59 p.m. ET.
Voting matters and shareholder proposals
Proposal 1 seeks authority for the Board to amend the certificate of incorporation to effect a reverse stock split; the Board recommends For.
Proposal 2 seeks approval to adjourn the meeting to solicit additional proxies if votes are insufficient; the Board recommends For.
Shareholder rights and capital structure
Proposed reverse split ratio ranges from 1-for-8 to 1-for-15; the Board would select the ratio within 12 months after approval, without another stockholder vote.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Traws Pharma
- A reverse-split vote is central to efforts to retain Nasdaq listing compliance.TRAW
Proxy filing - A discretionary 1-for-8 to 1-for-15 split is proposed to address Nasdaq listing compliance.TRAWProxy filing
- Net loss widened, cash is limited, and milestone-based financing was secured.TRAWQ2 2026
- All proposals passed, including director elections and incentive plan changes; no questions raised.TRAWAGM 2026
- Registering up to $139.2M in securities to fund antiviral and oncology R&D amid financial uncertainty.TRAWRegistration filing
- Annual meeting seeks approval for director elections, incentive plan changes, and warrant issuances.TRAWProxy filing
- Shareholders will vote on directors, plan amendments, auditor ratification, and warrant share issuance.TRAWProxy filing
- Virtual meeting to vote on directors, incentive plan, auditor, share issuance, and governance.TRAWProxy filing
- Lead antivirals progress, $20M financing, and CEO change position for 2025 milestones.TRAWQ4 2024 & Study Update